These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12799623)

  • 61. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
    Tiersten A; Wo J; Jacobson C; Weitzman A; Horwich T; Hesdorffer C; Savage D; Troxel A
    Breast; 2004 Aug; 13(4):341-6. PubMed ID: 15325671
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer.
    Sayer HG; Schilling K; Vogt T; Blumenstengel K; Issa MC; Mügge LO; Kasper C; Kath R; Höffken K
    J Cancer Res Clin Oncol; 2003 Jun; 129(6):361-6. PubMed ID: 12884031
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
    Rodenhuis S; de Wit R; de Mulder PH; Keizer HJ; Sleijfer DT; Lalisang RI; Bakker PJ; Mandjes I; Kooi M; de Vries EG
    Ann Oncol; 1999 Dec; 10(12):1467-73. PubMed ID: 10643538
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.
    Vahdat L; Raptis G; Fennelly D; Hamilton N; Reich L; Tiersten A; Harrison M; Hudis C; Moore M; Yao TJ; Norton L; Crown J
    Clin Cancer Res; 1995 Nov; 1(11):1267-73. PubMed ID: 9815921
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Results of a prospective study with high-dose etoposide, thiotepa and carboplatin and peripheral blood stem cell rescue for high-risk stage II-IIIA and selected stage IV breast cancer patients.
    Gori S; Mosconi AM; Tabilio A; Falzetti F; Aristei C; Basurto C; Cherubini R; Latini P; Martelli MF; Tonato M; Colozza M
    Tumori; 2001; 87(3):138-41. PubMed ID: 11504367
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
    de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
    Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A pilot trial of tandem autologous peripheral blood progenitor cell transplantation following high-dose thiotepa and carboplatin in children with poor-risk central nervous system tumors.
    Ozkaynak MF; Sandoval C; Levendoglu-Tugal O; Jayabose S
    Pediatr Hematol Oncol; 2004; 21(7):635-45. PubMed ID: 15626020
    [TBL] [Abstract][Full Text] [Related]  

  • 68. GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.
    Elias AD; Mazanet R; Wheeler C; Anderson K; Ayash L; Schwartz G; Tepler I; Pap S; Pelaez J; Hunt M
    Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S25-9. PubMed ID: 1687204
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
    Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H
    Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer.
    Tomás JF; Pérez-Carrión R; Escudero A; López-Lorenzo JL; López-Pascual J; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Feb; 19(4):331-6. PubMed ID: 9051242
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
    J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
    Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
    Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Bajorin DF; Bosl GJ; Lyn P; Vlamis V
    J Clin Oncol; 1997 Jul; 15(7):2546-52. PubMed ID: 9215823
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
    Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer.
    deMagalhaes-Silverman M; Rybka WB; Lembersky B; Bloom EJ; Lister J; Pincus SM; Voloshin M; Wilson J; Ball ED
    Am J Clin Oncol; 1996 Apr; 19(2):169-73. PubMed ID: 8610643
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
    Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
    J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.